Regeneron REGN
Regeneron is a biopharmaceutical company that develops and commercializes innovative medicines for eye, inflammatory, and cancer diseases. Regeneron shows excellent financial health (net cash, liquidity 3.33) and an operating margin of 33.11%, with revenue growth of 16.7% and reasonable valuation (P/E 19.49, forward 12.94), although earnings growth is negative (-4.5%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Regeneron is a biopharmaceutical company that develops and commercializes innovative medicines for eye, inflammatory, and cancer diseases. Regeneron shows excellent financial health (net cash, liquidity 3.33) and an operating margin of 33.11%, with revenue growth of 16.7% and reasonable valuation (P/E 19.49, forward 12.94), although earnings growth is negative (-4.5%).
Score by category
| Category | Score |
|---|---|
| Financial health | 9.0 |
| Quality / Moat | 6.6 |
| Valuation | 6.0 |
| Growth | 5.7 |
| Dividend | 3.0 |
| Momentum | 7.5 |
| Risk & Context | 8.7 |
OVERALL SCORE: 6.8/10
Context and risks
Moderate regulatory risk in the US due to pressure on drug prices and possible drug pricing legislation, directly affecting biopharmaceutical companies like Regeneron.
News considered in the analysis
- Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent — La diversificación de Sanofi más allá de Dupixent reduce la dependencia de Regeneron de su socio, pero no es un evento directo para REGN.
- Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run — Opinión de valoración sin información nueva; el mercado ya ha descontado la subida.
- Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts — Reafirma el crecimiento de EYLEA HD y Dupixent, con catalizadores de pipeline que podrían impulsar ingresos futuros.
- Is Regeneron Stock a Bargain Below $800? — Artículo de opinión sin datos nuevos; no aporta información material.
- Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine — Noticia sobre Sanofi, no sobre Regeneron; sin impacto directo en los fundamentales de REGN.
Verdict: Hold or buy on dips, given the solid balance sheet and pipeline catalysts, but watch regulatory pressure on pricing.
Main risk: The main risk is US regulatory pressure on drug pricing, which could compress margins on key products like EYLEA HD and Dupixent.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →